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Mutations inACTA2, encoding the smoothmuscle cell (SMC)-specific isoform of a-actin (a-SMA), cause thoracic
aortic aneurysms and dissections andocclusive vascular diseases, including early onset coronary artery disease
and stroke. We have shown that occlusive arterial lesions in patients with heterozygousACTA2missense muta-
tionsshow increasednumbersofmedial orneointimalSMCs.ThecontributionofSMChyperplasia to thesevascu-
lar diseases and the pathways responsible for linking disruption ofa-SMA filaments to hyperplasia are unknown.
Here, we show that the loss ofActa2 in mice recapitulates the SMC hyperplasia observed inACTA2mutant SMCs
anddeterminethecellularpathwaysresponsible forSMChyperplasia.Acta22/2miceshowedincreasedneointimal
formation following vascular injury in vivo, and SMCs explanted from these mice demonstrated increased
proliferation and migration. Loss of a-SMA induced hyperplasia through focal adhesion (FA) rearrangement, FA
kinase activation, re-localization of p53 from the nucleus to the cytoplasm and increased expression and ligand-
independent activation of platelet-derived growth factor receptor beta (Pdgfr-b). Disruption of a-SMA in wild-
type SMCs also induced similar cellular changes. Imatinib mesylate inhibited Pdgfr-b activation and Acta22/2
SMCproliferation in vitroandneointimal formationwithvascular injury invivo. Lossofa-SMA leads toSMChyper-
plasia in vivo and in vitro through a mechanism involving FAK, p53 and Pdgfr-b, supporting the hypothesis that
SMC hyperplasia contributes to occlusive lesions in patients withACTA2missense mutations.
INTRODUCTION
Smooth muscle cells (SMCs) contract in response to changes in
pulse pressures through cyclic interaction between thin and thick
contractile filaments, composed of the SMC-specific isoforms of
a-actin (a-SMA) andmyosin heavy chain, respectively. Hetero-
zygous mutations in a-SMA, encoded by ACTA2, predispose to
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thoracic aortic aneurysms and acute aortic dissections, along
with a variety of occlusive vascular diseases, including early
onset coronary artery disease (CAD)and stroke,Moyamoya-like
cerebrovascular disease and primary pulmonary hypertension
(1–3). Pathology of the occlusive arterial lesions in patients
with ACTA2 mutations shows increased numbers of SMCs in
the neointimal or medial layers of the artery, but a paucity of
lipid and calcium depositions typically found in atherosclerotic
lesions (2,4). Primary cultures of aortic SMCs explanted from
patients with ACTA2 mutations show fewer a-SMA filaments
when compared with control SMCs. Additionally, the mutant
SMCs proliferate more rapidly when compared with SMCs
explanted from donor controls. SMC proliferation occurs
during formation of atherosclerotic occlusive lesions, but a
role of genetically triggered SMC hyperplasia as a cause of vas-
cular occlusive disease has not been extensively investigated.
A likely axis linking disruption of a-SMA to increased prolif-
eration is the myocardin-related transcription factor-serum re-
sponse factor (MRTF-SRF) axis, which links the dynamic flux
of a-SMA from monomers to filaments with proliferation (5).
Unlike myocardin which is constitutively nuclear, MRTFs con-
tinuously shuttle between the nucleus and cytoplasm, with local-
ization and activity of MRTFs dependent on cytoplasmic actin
polymerization, aswell as nuclear import and exportmechanisms
(6). MRTFs bind monomeric actin and, as actin polymerizes,
MRTFs dissociate from actin, unmasking a nuclear localization
sequence and facilitating nuclear import via an importin a/
b-dependent mechanism (7). In the nucleus, MRTFs bind to the
transcriptional co-activator SRF to induce the transcription of
SMC contractile genes. As actin filaments are disrupted, mono-
mers accumulate and MRTFs are shuttled out of the nucleus and
are sequestered in the cytoplasm by binding to monomeric
actin. This leads to the decreased expression of contractile
genes, by allowing SRF to bind to ternary complex factors and ac-
tivate transcription of a subset of SRF-regulated growth respon-
sive genes, such as Fos (8,9). Activation of these genes
increases the responsiveness of the cells to proliferative cell sig-
naling pathways and growth factors, such as platelet-derived
growth factor beta (PDGF-BB).
We sought to determine whether loss of a-SMA leads to SMC
hyperplasia and identify the cellular pathways responsible for the
increased proliferation. To study cellular proliferationwith loss of
a-SMAfilaments,wechose toexamineamousemodeldeficient in
a-SMA (Acta22/2 mice), which was previously reported to have
normalvasculardevelopmentbutcompromisedvascularcontract-
ile force, tone and blood flow (10). Aortic SMCs explanted from
thesemicearehyperplastic invitroand invivo, but theproliferation
is not dependent on MRTF-A localization to the cytoplasm.
Instead, we found that the cellular pathways contributing to the
increasedproliferation involveaberrant focal adhesion (FA) local-
ization and activation, leading to altered cellular localization of
p53 and increased expression and ligand-independent activation
of platelet-derived growth factor receptor beta (Pdgfr-b).
RESULTS
Loss of a-SMA leads to increased SMC proliferation and
migration and nuclear localization of MRTF
Aortic SMCs were explanted separately from the ascending
and descending aortas of 4-week-old Acta22/2 mice since
SMCs from these regions of the aorta arise from two different
sources, neural crest-derived andmesenchymal-derived progeni-
tor cells, respectively (11). Acta22/2 SMCs explanted from both
aortic regions proliferated and migrated more rapidly than wild-
type (WT) SMCs (Fig. 1A and B, Supplementary Material,
Fig. S1A and B). We utilized ascending SMCs for further study
because these cells are likely of the same embryonic origin as
the SMCs found in occlusive cerebral artery lesions in patients
with ACTA2mutations, based on the location of these lesions (2).
To determine whether deficiency in a-SMA also increases
cellular proliferation in response to vascular injury in vivo, we
used a flow-cessation injury model of carotid artery to reprodu-
cibly induce injury (12). Carotid injurymodels have been exten-
sively used to study the effects of vascular injury on SMCs and
both proliferation and migration of SMCs play a role in the
degree of vessel stenosis (12,13). Three weeks post carotid liga-
tion, Acta22/2 mice showed exaggerated neointimal formation
compared with WT mice based on assessment of the intima/
media ratio, neointimal area andpercent stenosis of ligated arter-
ies (Fig. 1C). Additionally, labeling of proliferative cells with
BrdU and subsequent immunostaining showed an increase in
positively stained nuclei in Acta22/2 arteries 1 week post liga-
tion (Fig. 1D). Thus, SMC hyperplasia is evident both in vitro
and in vivo with loss of a-SMA.
Acta22/2 aortas were previously reported to have increased
a-skeletal actin (encoded by Acta1), and Acta22/2 pulmonary
SMCs were reported to have increased expression of SMC
g-actin (g-SMA, encoded by Actg2) (10,14). We did not detect
Acta1 expression in our Acta22/2 SMC explants. However,
there was increased Actg2mRNA (Fig. 1E). The lack of specific
g-SMA antibodies prevented the assessment of cellular g-SMA
protein levels. Further analysis of actin isoforms in these cells
showed no difference in protein levels of b-actin or total actin
between mutant andWT SMCs (Fig. 1F, Supplementary Mater-
ial, Fig. S2A).
To determine whether the MRTF-SRF axis is altered in the
Acta22/2 SMCs,weassessed theexpression levels of contractile
genes known to contain CArG boxes and be responsive to
MRTF-SRF binding in the promoter region. The Acta22/2
SMCs had increased expression of MRTF-SRF-dependent
genes, including Tagln and Cnn1 (encoding SM22a and
calponin-1, respectively), and corresponding increases in cellular
levels of these proteins by immunoblot analysis (Fig. 2A and B).
SinceMRTF-A is a more potent transcriptional coactivator than
MRTF-B in SMCs, MRTF-A cellular location was assessed in
the mutant SMCs (5,15). Consistent with increased contractile
gene expression, immunofluorescent staining showed increased
co-localization of nuclear staining with MRTF-A signal in
Acta22/2 SMCs compared with WT SMCs (Fig. 2C and D,
Supplementary Material, Fig. S2C). Additionally, expression
of Fos, an SRF-regulated growth responsive gene, was not
increased in Acta22/2 SMCs (Fig. 2E). Therefore, the hyper-
plastic Acta22/2 SMCs are differentiated, as defined by
increased expression of differentiation marker proteins and
nuclear MRTF-A localization.
Interestingly, F-to-G actin assays showed no difference in the
ratio of total polymerized to unpolymerized actin in the mutant
SMCs compared with WT SMCs (Fig. 2F, Supplementary Ma-
terial, Fig. S2B). However, atomic force microscopy revealed
a 2.5-fold increase in local cell stiffness of Acta22/2 SMCs
(Fig. 2G).
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Figure 1. Acta22/2 SMCs show increased proliferation and migration in vitro and increased proliferation in vivo with vascular injury. (A) SMCs isolated
from ascending aortas of 4-week-old Acta22/2 mice show increased proliferation, as quantified by BrdU incorporation, compared with SMCs explanted from
WT mice. ∗P , 0.05. Data shown are representative of three independent experiments from three different explants. (B) Migration assays were performed using
5 ng/ml PDGF-B as a chemoattractant, and showed increased Acta22/2 SMC migration compared with WT SMCs. Five high-powered fields per sample were
counted, and data shown are representative of three independent experiments. ∗P, 0.05. Scale bars represent 200 mm. (C) Left carotid arteries were ligated and
tissue was harvested 3 weeks post injury. Carotid arteries from Acta22/2 mice (n ¼ 7) showed increased neointimal area, ratio of intimal/medial area and degree
of stenosis of the lumen compared with carotid arteries obtained from a similar location in WT mice (n ¼ 7). ∗P , 0.05. Arrows denote neointimal layer. Scale
bars represent 200 mm. (D) Following carotid artery ligation,micewere injectedwith BrdU2 h prior to sacrifice. Oneweek post ligation, an increase in BrdUpositive
nuclei was observed in Acta22/2 mice. Top: adventitia. Bottom: neointima. Arrows denote BrdU+ cells. ∗∗P , 0.01. Scale bars represent 100 mm. (E) Actg2 gene
expressionwasquantifiedviaQ-PCR,andwas increased inActa22/2 SMCs. ∗P , 0.05. (F) Immunoblottingofb-actin showedsimilar cytoplasmic actin levels inWT
and Acta22/2 SMCs. Error bars represent+SD.
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Loss ofa-SMA alters FA localization and size, and increases
activation of FA kinase
FAs in the Acta22/2 SMCs were investigated since increased
cellular tension has been shown to drive FA maturation and
increased activation of FA-dependent signaling (16), and previ-
ous studies identified increased FA kinase (FAK) activity in
renal myofibroblasts in Acta22/2 mice (17). FA number and
sizewere assessed in theActa22/2 SMCs through immunofluor-
escence using an anti-vinculin antibody and total internal reflec-
tion fluorescence (TIRF) microscopy. These analyses
demonstrated redistribution of FAs from dispersion across the
cell body to the accumulation at the periphery of the cells, with
increased individual FA size but decreased numbers of FAs in
Acta22/2 SMCs compared with WT SMCs (Fig. 3A and B). In
addition to increased FA size, there was increased phosphoryl-
ation of FAK at Tyr297 in FAs by TIRF microscopy, indicative
of increased FAK activation (Fig. 3A and B). Increased cellular
levels of pFAK, along with a corresponding increase in total
FAK, were also detected by immunoblot analysis (Fig. 3C).
SinceFAK is capable of drivingRac1 activation and suppressing
RhoA activation (18,19), Rac1 and RhoA activation were
Figure2.Acta22/2 SMCsarenotdedifferentiated. (A)Contractile geneexpressionwasanalyzedusingquantitativePCRandshowed increasedCnn1 (calponin-1) and
Tagln (SM22a) inActa22/2 SMCscomparedwithWT. ∗P , 0.05. (B) Immunoblot analysis showedcorresponding increases in calponin-1andSM22aprotein levels
inActa22/2 SMCs. Black bars representWT andwhite bars representActa22/2 SMCs. (C andD) Cells were immunofluorescently labeled withMRTF-A antibody,
and nuclear versus cytoplasmic fluorescence was quantified. MRTF-A staining is shown in black-and-white; color panels are included in Supplementary Material,
Figure S2C. More MRTF-A is colocalized with nuclear DAPI in Acta22/2 SMCs than in the WT cells. Scale bars represent 50 mm. ∗∗P , 0.01. (E) Expression
ofFos, a gene known to be responsive to changes inMRTF-dependent signaling, was not significantly altered inActa22/2 SMCs comparedwithWT cells. (F) Ultra-
centrifugationwas used to separate supernatant fraction (S) containingG-actin from the pellet fraction (P) containingF-actin.No difference in the ratio of unpolymer-
ized supernatant fraction to polymerized pellet fraction was observed between WT and Acta22/2 SMCs. (G) Atomic force microscopy was used to quantify cell
stiffness. Local cell stiffness is significantly increased in Acta22/2 SMCs. ∗P , 0.05. Error bars in (D) represent+95% CI; all other error bars represent+SD.
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assessed. There was increased Rac1 activation in Acta22/2
SMCs, both without and with stimulation with lysophosphatidic
acid [LPA, which induces Rac1 activation in SMCs (20)] as
expected, but RhoA activationwas not suppressed and remained
similar between mutant and WT SMCs (Fig. 3D).
FAK activates multiple downstream pathways that can con-
tribute to cellular proliferation (21,22). Increased
phosphorylation of both Akt (pSer473) and ERK1/2 (pThr202/
Tyr204) was present in Acta22/2 SMCs compared with WT
SMCs (Fig. 3E, SupplementaryMaterial, Fig. S3A andB). Add-
itionally, there were increased levels of phosphorylated p70S6
kinase, indicative of mTOR activation, and decreased levels of
p27kip1, both ofwhich are cellular changes observedwithAkt ac-
tivation (23) (Fig. 3E, SupplementaryMaterial, Fig. S3A andB).
Figure 3. Acta22/2 SMC proliferation is in part driven by alterations in FA-dependent signaling. (A) Vinculin and pTyr397 FAK were quantified using TIRF mi-
croscopy. FAs were localized to the cell periphery in Acta22/2 SMCs, whereas FAs were diffusely located across the cell body in theWT cells. Scale bars represent
20 mm. (B) TIRF microscopy was used as in (A), and quantification of vinculin, pFAK, FA number and FA size using TIRF microscopy show increased size and
vinculin and pFAK content in FAs in Acta22/2 SMCs, but a decrease in the overall number of FAs per cell. Data were obtained from at least 10 random cells per
each condition using SlideBook software (Intelligent Imaging Innovations, Denver, CO, USA), and were normalized and expressed as a ratio of protein area:cell
area. ∗P , 0.05. (C) Immunoblotting revealed increased pFAK levels in Acta22/2 SMCs. (D) G-LISA identified significantly increased Rac1 activation in
Acta22/2 SMCs, both at baseline and 15 min post stimulation with LPA but no change in RhoA activation. Black bars represent WT and white bars represent
Acta22/2 SMCs. (E) Immunoblots showed increased levels of pAkt and pERK in Acta22/2 SMCs. (F) Proliferation assays using BrdU incorporation indicate
that two distinct FAK inhibitors decreased Acta22/2 SMC proliferation to levels similar to WT SMCs. PF-562271 (PF-271) and PF-573228 (PF-228) were each
used at a 1 mM concentration. Bars on graph are represented as in (C). Data are representative of at least three independent experiments, andP-values were calculated
using a Student’s t-test. ∗P , 0.05. (G) Cells were treated with the FAK inhibitor PF-228, and protein lysates were immunoblotted for pERK and pAkt. PF-228 par-
tially blocked ERK and Akt phosphorylation. Bars on graph are represented as in (C). All error bars represent+SD. ∗P , 0.05.
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To determine whether FAK-dependent pathways contribute to
the increased proliferation in the mutant SMCs, two different
FAK inhibitors, PF-562271 and PF-573228, were used
(24,25). Both inhibitors attenuated proliferation of both mutant
and WT SMCs and decreased mutant SMC proliferation to the
same level as theWT(Fig. 3F). Immunofluorescent staining con-
firmed that PF-573228 blocked FAK activation (Supplementary
Material, Fig. S3C). Interestingly, although the FAK inhibitor
decreased proliferation and levels of pFAK in FAs, it only par-
tially blocked ERK1/2 and Akt activation (Fig. 3G).
Loss of a-SMA leads to increased levels of Pdgfr-b and
decreased nuclear localization of p53
Activation of Pdgfr-b is a major mitogenic pathway for SMCs
and also leads to activation of ERK1/2 and Akt (26). Since the
treatment with the FAK inhibitors only partially blocked
ERK1/2 and Akt signaling in Acta22/2 SMCs, the expression
and activation of Pdgfr-bwas assessed. Pdgfrb gene expression
and Pdgfr-b protein levels were significantly increased in
Acta22/2 SMCs comparedwithWTSMCs, and there was a cor-
responding increase in the activation of the receptor as assessed
by increased phosphorylation of Tyr1021 (Fig. 4A and B; Sup-
plementary Material, Fig. S4A). Therefore, Pdgfr-b signaling
is increased in Acta22/2 SMCs due to the increased levels of
the receptor. To determine whether there was also increased sta-
bility of Pdgfr-b protein in the mutant cells, Acta22/2 and WT
SMCs were exposed to cycloheximide to block protein transla-
tion for various time points up to 8 h. Pdgfr-b levels decreased
more rapidly in the WT than mutant cells, suggesting that
Pdgfr-b was degraded more slowly in the mutant cells (Supple-
mentary Material, Fig. S4B). Thus, in Acta22/2 SMCs, Pdgfrb
transcript and Pdgfr-b protein levels are increased, and the
protein is more stable than in WT SMCs.
Treatment with either the FAK inhibitor PF-573228 or the
mTOR inhibitor rapamycin significantly attenuated Pdgfr-b ex-
pression at both the mRNA and protein levels (Fig. 4C and D;
Supplementary Material, Fig. S4C). In contrast, inhibition of
ERK1/2 did not alter Pdgfrb expression (data not shown). The
tumor suppressor p53 is a known transcriptional repressor of
Pdgfrb expression in other cell types. Studies in cancer cells
have shown that either FAK or mTOR activation can alter p53;
FAK activation decreases p53 activity, and mTOR activation
decreases nuclear localization of p53 (27–30). Assessment of
the localization of cellular p53 by immunofluorescence indi-
cated localization predominantly in the nucleus in WT SMCs,
but primarily cytoplasmic localization in Acta22/2 SMCs.
Treatment with the FAKormTOR inhibitor decreased cytoplas-
mic and increased nuclear p53 inActa22/2 SMCs (Fig. 4G). The
ability of a pharmaceutical activator of p53, CP-31398 (31), to
repress Pdgfrb expression and alter p53 cellular localization
was also assessed. CP-31398 decreased Pdgfrb gene expression
and Pdgfr-b protein levels in Acta22/2 SMCs after 4 h at a dose
of 15 mg/ml with no evidence of toxicity (31) (Fig. 4E and F,
Supplementary Material, Fig. S4D). CP-31398 also increased
the intensity of p53 staining throughout the cell and significantly
increased the ratio of nuclear to cytoplasmic staining of p53
(Fig. 4G). CP-31398 completely inhibited all cellular prolifer-
ation in both Acta22/2 and WT SMCs (data not shown). These
data suggest that in Acta22/2 SMCs, a mechanism involving
FAK and mTOR activation re-localized p53 to the cytoplasm,
leading to increased Pdgfrb expression and protein levels.
Pdfgr-b activation in Acta22/2 SMCs is ligand independent
and influenced by cellular reactive oxygen species levels, and
drives Acta22/2 SMCs proliferation in vitro and in vivo
Neutralizing antibody and conditioned media experiments were
performed to determine whether the increased Pdgfr-b activa-
tion in the Acta22/2 SMCs was ligand dependent. Exogenous
PDGF-BB increased Pdgfr-b activation, and pretreatment with
PDGF-BB neutralizing antibody completely prevented the
PDGF-BB-induced increase as reported by others but did not
further reduce Pdgfr-b activation in the Acta22/2 SMCs (32).
Additionally, incubation with the antibody failed to decrease
Pdgfr-b activation in untreated Acta22/2 SMCs. Conditioned
media fromActa22/2 SMCs did not increase Pdgfr-b activation
in WT SMCs, providing further evidence supporting ligand-
independent activation of Pdgfr-b in Acta22/2 SMCs (Fig. 5A
and B; Supplementary Material, Fig. S5A and B).
Increased cellular reactive oxygen species (ROS) have been
shown to promote ligand-independent activation of Pdgfr-b by
inhibiting the protein tyrosine phosphatase responsible for
de-phosphorylating the activated receptor (33,34).Additionally,
Rac1 activation has been associatedwith increasedROSproduc-
tion in SMCs (35). To determine whether ROS contribute to
Pdgfr-b activation in Acta22/2 SMCs, we quantified ROS
levels by staining Acta22/2 SMCswithMitoSOX, a fluorescent
probe for mitochondrial ROS production. Flow cytometry
showed significantly higher fluorescent signal in Acta22/2
SMCs than theWT, indicating increased ROS (Fig. 5C). The fla-
voenzyme inhibitor diphenyleneiodonium (DPI) was able to
inhibit Pdgfr-b activation in a dose-dependent manner in
Acta22/2 SMCs and also blocked cellular proliferation at a
dose of 5 mM (Fig. 5D, Supplementary Material, Fig. S5E). In
addition, both rotenone and antimycinA,whichblockmitochon-
drial respiratory complexes I and III, respectively, attenuated
Pdgfr-b activation andproliferation inActa22/2 SMCs (Supple-
mentary Material, Fig. S5C and D).
Acta22/2 SMCs were exposed to imatinib to determine
whether blocking tyrosine kinase receptor activation could at-
tenuate proliferation. Treatment with 10 mM imatinib decreased
proliferation of Acta22/2 SMCs to the level of WT SMCs
(Fig. 5E). Immunoblot analysis confirmed that imatinib effect-
ively blocked phosphorylation of Pdgfr-b (Supplementary Ma-
terial, Fig. S5F). To determine the role of Pdgfr-b in
neointimal formation in vivo, daily intraperitoneal injections
of imatinib (50 mg/kg/day) were given after carotid artery liga-
tion. Imatinib effectively blocked neointimal formation after
carotid artery injury inActa22/2mice, but also blocked neointi-
mal formation in theWTmice as has previously been reported in
other systems (36) (Fig. 5F).
Ana-SMAdisruptingpeptide inducesphenotypic changes in
WT SMCs similar to Acta22/2 SMCs
To determine whether disruption of a-SMA filaments in WT
SMCs leads to FA alterations, altered p53 cellular localization
and increased expression of Pdgfr-b, we used a cell-permeable
peptide that disrupts a-SMA filament formation (aSMA-fp)
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Figure 4. Increased Pdgfr-b expression and stability in Acta22/2 SMCs. (A) Quantitative PCR showed increased Pdgfrb gene expression in Acta22/2 SMCs. ∗P ,
0.05. (B) Immunoblots showed increased Pdgfr-b protein expression and phosphorylation at Tyr1021 in Acta22/2 SMCs. (C and D) Cells were treated with either
mTOR inhibitor (rapamycin) or FAK inhibitor (PF-228). Treatmentwith either inhibitor significantly reducedPdgfrb gene (C) and Pdgfr-b protein (D) expression in
Acta22/2 SMCs. ∗P , 0.05. Black bars represent WT and white bars represent Acta22/2 SMCs. (E and F) Cells were treated with an activator of p53, CP-31398.
Pdgfrbgene (E) andPdgfr-b protein (F) expressionwere significantly reduced inActa22/2 SMCs followingCP-31398 treatment. ∗P , 0.05. Bars on graph are repre-
sented as in (C). (G) Cells were immunofluorescently labeled using a p53 antibody. p53 is localized predominantly in the nucleus inWTSMCs, but predominantly in
the cytoplasm inActa22/2 SMCs. Treatmentwith rapamycin, FAK inhibitor or p53 activator drives p53 back into the nucleus inActa22/2 SMCs. ∗P, 0.05. Bars on
graph are represented as in (C).
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and a control peptide that disrupts a skeletal actin (a-SKA) but
not a-SMA filaments (aSKA-fp) (37). Immunofluorescence
analysis of a-SMA filaments and total actin filaments was per-
formed on WT SMCs following 24 h of peptide treatment.
Cells exposed toaSKA-fp hadminimal loss ofa-SMAfilaments
when compared with control SMCs, whereas SMCs treated with
aSMA-fp showed no a-SMA filaments and no pools of mono-
merica-SMA (Fig. 6A, SupplementaryMaterial, Fig. S6A). Im-
munofluorescence of FAs using an anti-vinculin antibody
showed localization of FAs to the cell periphery in the
aSMA-fp treated cells but not in the aSKA-fp treated cells
(Fig. 6A and B, Supplementary Material, Fig. S6B). Staining
Figure 5.Pdgfr-b activation inActa22/2 SMCs is ligand-independent, regulated in part byROS, and a contributor toActa22/2 SMChyperplasia in vitro and in vivo.
(A) Cells were treated with a neutralizing antibody against PDGF-BB (1 mg/ml). Neutralizing antibody treatment effectively blocked PDGF-BB (20 ng/ml) induced
receptor phosphorylation but failed to reduce baseline receptor activation inActa22/2 SMCs. (B)WTcellswere incubatedwith conditionedmedia fromeitherWTor
Acta22/2 SMCs.Acta22/2 conditionedmedia failed toactivatePdgfr-b inWTSMCs.Anequivalent amountofcell lysate fromuntreatedActa22/2 SMCswasusedas
a positive control. (C) Cells were trypsinized, incubated with a MitoSOX probe for 20 min to label mitochondrial ROS and subjected to flow cytometric analysis.
Mitochondrial-derived ROS levels were increased in Acta22/2 SMCs. (D) Cells were treated with NADPH oxidase inhibitor (DPI). DPI treatment reduced
Pdgfr-b phosphorylation inActa22/2 SMCs and blocked proliferation ofActa22/2 SMCs at a dose of 5 mM. (E) Imatinibmesylate (IM) at a dose of 10 mM decreased
Acta22/2 SMC proliferation in vitro to levels similar to WT SMCs. ∗P , 0.05. Black bars represent WT and white bars represent Acta22/2 SMCs. (F) Left carotid
arteries inmicewere ligated, andharvested21dayspost injury.Micewere giveneither vehicle or imatinibmesylate (50 mg/kg/day) 2hprior to injury andonceper day
thereafter. Imatinib completely prevents neointimal formation in bothWTandActa22/2 arteries. Black arrows indicate the border between themedial and neointimal
layers.n ¼ 6miceper experimental group.Blackbars ongraph represent vehicle treatedandgreybars represent imatinib treatedmice. ∗P , 0.05. Scale bars represent
200 mm. All error bars represent+SD.
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Figure6.Apeptide that disruptsa-SMAfilaments in cells leads to FA relocalization to the periphery and increasedPdgfrbgene expression inWTSMCs. (A–E).WT
cells were treated with either an SMA-disrupting peptide (aSMA-fp) or control peptide targeting skeletal a-actin (aSKA-fp) and harvested for analysis. (A) Immu-
nostaining ofa-SMA showed that actin filaments are disrupted 24 h after addition of 1 mg/mlaSMA-fp as opposed to no disruption in untreated cells or cells treated
with 1 mg/mlaSKA-fp. The increased green background in theaSMA-fp-treated cells is most likely due to cross-reaction of thea-SMAantibodywith theaSMA-fp
peptide. Immunostaining with an anti-vinculin antibody showed relocalization of the FAs to the periphery of the interface between the cell and the culture dish in
aSMA-fp-treated SMCs. Scale bars represent 20 mm. (B) The number of FAs was quantified, and showed a difference in adhesion localization between SKA-fp
and SMA-fp-treated WT SMCs. ∗P , 0.05. (C) Q-PCR data showing increased Pdgfrb gene expression 24 h after adding aSMA-fp but not aSKA-fp. Treatment
with either PF-228 or rapamycin rescued this increased expression. ∗P, 0.05. Combined data from three independent experiments are shown. Black bars represent
WT untreated, grey bars represent SKA-fp treated and white bars represent SMA-fp-treated cells. All error bars represent+SEM. (D and E) Quantitation (D) and
images (E) showing altered cellular localization of p53 after treatment with SMA-fp but not SKA-fp. This change is rescued by treatment with either PF-228 or rapa-
mycin. Bars on graph are represented as in (C). ∗P, 0.05. Scale bars represent 100 mm.
Human Molecular Genetics, 2013, Vol. 22, No. 15 3131
for MRTF-A revealed that, similar to the Acta22/2 SMCs, cells
treated with the aSMA-fp peptide have increased nuclear local-
ization of MRTF-A (Supplementary Material, Fig. S7A and B).
Furthermore, disruption of a-SMA filaments in WT SMCs with
aSMA-fp led to significantly increased Pdgfrb gene expression
(Fig. 6C). Co-treatment with aSMA-fp and an inhibitor of FAK
(PF-228) or of mTOR (rapamycin) blocked the increase in
Pdgfrb expression associated with a-SMA disruption by the
peptide (Fig. 6C). Immunofluorescence staining for p53 con-
firmed that treatment with aSMA-fp, but not aSKA-fp,
reduced the nuclear localization of p53, and inhibition of
either FAK or mTOR blocked this decrease in nuclear localiza-
tionwithaSMA-fp treatment (Fig. 6D andE). The serum starva-
tion required for peptide treatment affected the ability to assess
proliferation after peptide treatment; however, the aSMA-fp
treated cells but not the aSKA-fp treated cells show a reprodu-
cible andmarginally statistically significant increase inBrdU in-
corporation (Supplementary Material, Fig. S6C). The
combination of serum deprivation and CP-31398 treatment
causedcell death; therefore,wewereunable to confirmincreased
nuclear localization of p53 with CP-31398 treatment. Thus, dis-
ruption of the a-SMA filaments in WT SMCs leads to altered
FAs, increasedPdgfrb expression and cytoplasmic p53 localiza-
tion, recapitulating the phenotypic features of the Acta22/2
SMCs.
DISCUSSION
We previously observed decreased a-SMA filaments and
increased proliferation in SMCs explanted from patients with
ACTA2 mutations (2). Furthermore, occlusive vascular lesions
in these patients are characterized by increased numbers of
medial or intimal SMCs. The results presented here demonstrate
that loss of a-SMA filaments in a mouse model increases SMC
proliferation in vitro and leads to excessiveneointimal formation
with vascular injury in vivo. Although the carotid ligationmodel
used in this study is not directly translatable into a pathological
process in humans, it does provide a well-established, useful
model for studying the proliferative response of Acta22/2
SMCs to vascular injury (12,13,38). Thus, these data support
the hypothesis that a hyperplastic response of the SMCs contri-
butes to the increased risk of occlusive vascular diseases in
patients with ACTA2mutations. Coronary arteries from patients
with ACTA2 mutations display lesions with minimal lipid and
calcium deposits but enriched in SMCs, suggesting that SMC
hyperplasia may represent an alternative molecular pathway
from a single gene mutation to CAD. It is also important to
note that recent studies have implicated a similar role of genetic-
ally triggered SMC hyperplasia in CAD in the general popula-
tion. A locus on 9p21 harbors genetic polymorphisms that
increased the risk for CAD (39) and deletion of an orthologous
region in mice caused excessive aortic SMC proliferation (40).
Further studies are needed to confirm the molecular basis
of the atherosclerotic risk associated with the 9p21 locus;
however, our data presented here also support a role for a genet-
ically triggered hyperplastic response of SMCs in the pathogen-
esis of occlusive vascular diseases.
TheActa22/2 SMCs proliferate more rapidly thanWTSMCs
and display a phenotype divergent from the classical definition
of dedifferentiated SMCs, specifically increased expression of
contractile protein with MRTF-A localized to the nucleus and
increased SMC proliferation. Previously, evidence of adult
SMC phenotypes divergent from the canonical differentiated
versus proliferative cells as defined by the MRTF-SRF axis
have been postulated but poorly described (41).Dedifferentiated
SMCs in advanced atherosclerotic lesions have been shown to
exhibit low rates of proliferation (42), and loss of Kru¨ppel-like
factor 4 inhibits both SMC differentiation and proliferation
(43). During development, vascular SMC precursors are
highly proliferative while expressing increasing amounts of
SMC-specific contractile proteins (44). The data presented
here support that adultmouse SMCs can assume a simultaneous-
lyproliferative anddifferentiated phenotype andprovide a cellu-
lar mechanism by which SMCs assume this phenotype.
Surprisingly, despite the loss of a-SMA, there was not a sig-
nificant change in the amount of total actin expression, and cel-
lular tension was increased. The loss of a-SMA increased the
expression of Actg2 and total cellular actin levels remained un-
changed when compared with WT SMCs. The g-SMA isoform
is predominant in the gut, where visceral SMCs undergo
phasic contraction, and g-actin isoforms in particular have
been shown to be more dynamic than other isoforms during
muscle contraction (45). The substitution of g-SMA for
a-SMA, in conjunction with increased expression of other con-
tractile proteins driven by MRTF transcriptional activity, could
be responsible for the increased cell stiffness. It is important to
note that increased Actg2 expression in Acta22/2 SMCs was
documented, but we were not able to confirm increased
g-SMA protein levels in these SMCs due to the lack of a specific
g-SMA antibody. However, based on the data showing that the
loss of a-SMA is not associated with decreased total cellular
actin levels, we can conclude that the protein levels of other
actin isoforms are increased, and the increased expression of
Actg2 suggests that g-SMA is one of the isoforms increased.
Deficiency of a-SMA and increased stiffness in Acta22/2
SMCs was associated with altered localization of FAs at the
cell periphery, enlargement of the FAs based on vinculin
content and excessive activation of FAK when compared with
WT cells (Fig. 7). Following formation of nascent FAs at the
cell periphery, the enlargement and maturation of FAs are de-
pendent on further force generation by the cell (46,47). In myo-
fibroblasts, FAmaturation has been demonstrated to specifically
require a-SMA force generation (48). Furthermore, both
a-SMA expression and functional, force-generating actin fila-
ments are required for assembly and maturation of FAs in
cells, a process driven by FAK (48–50). Our data suggest
instead that the loss of a-SMA leads to the formation of FAs
with increased size and continued FAK activation. The increase
in cell stiffness in Acta22/2 SMCs is consistent with these find-
ings; increased cell stiffness has been shown to correspond with
an increase in both cytoskeletal tension and FA size, leading to
the formation of so-called supermature FAs (51). Interestingly,
these ‘supermature’ FAs in Acta22/2 SMCs were also asso-
ciated with increased activation of Rac1, but no change in acti-
vation of RhoA. Rac1 and RhoA are usually reciprocally
regulated. For example, when smooth muscle myosin motor
function is disrupted by a missense mutation in the motor
domain, MYH11 R247C, the SMCs have smaller FAs, with
increased Rac1 and decreased RhoA activation (52). The loss
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ofRhoAactivation decreases actin polymerization and therefore
MRTF-A is cytoplasmic localized, and the cells assume a dedif-
ferentiated phenotype. Other cellular changes in the Acta22/2
SMCs, such as increased mTOR signaling or decreased p27kip1
levels, have previously been reported to increase the activation
of cellular RhoA andmay contribute tomaintainingRhoA activ-
ity in the Acta22/2 SMCs (53,54).
In addition to FAK activation, the Acta22/2 SMCs displayed
increased expression and activation of Pdgfr-b, and increased
cytoplasmic localization of p53 when compared with WT
SMCs. The tumor suppressor p53 has previously been identified
as a transcriptional repressor of Pdgfrb in cancer cells (29). We
further determined that inhibition of either FAK or mTOR sup-
pressed the expression of Pdgfrb and restored the nuclear local-
ization of p53 in Acta22/2 SMCs. Previous studies have
reported a direct interaction between FAK and p53 in cancer
cells (55). This interaction was mapped to a region of FAK
that includes the major phosphorylation site required for FAK
activation, tyrosine 397 (56). Additionally, it has also been
shown that inhibition of mTOR leads to p53 re-localization
from the cytoplasm to the nucleus in multiple cancer cell lines
(30). We were also able to show that a p53-activating drug sup-
pressed Pdgfrb expression and re-localized p53 from the cyto-
plasm to the nucleus in Acta22/2 SMCs. All these data
suggest that in Acta22/2 SMCs, excessive activation of FAK
and/or mTOR leads to p53 re-localization from the nucleus to
the cytoplasm and increased expression of Pdgfrb (Fig. 7).
Further studies are need to confirm that p53 represses Pdgfrb
transcription in SMCs and determine specific mechanisms by
which increased FAK and mTOR activation in the Acta22/2
SMCs results in the altered cellular localization of p53.
Our data utilizing a peptide that specifically disrupts a-SMA
filaments suggest that these pathways are directly relevant to
human patients with ACTA2 mutations, who have disruption
rather than loss of a-SMA filaments. Peptide treatment was
chosen over siRNA knockdown since a-SMA is present but
not formed properly into filaments in ACTA2 mutant SMCs.
SMCs exposed to the disrupting peptide recapitulated many of
the phenotypic changes in the Acta22/2 SMCs, including
altered FA localization, reduced nuclear localization of p53
and increased Pdgfrb gene expression. The ACTA2 mutations
identified in families with thoracic aortic disease and occlusive
vascular lesions are primarily missense mutations predicted to
produce mutant a-SMA monomers, and this was confirmed
via immunofluorescence (1,2). Based on our current understand-
ing, we hypothesize that mutant a-SMA will alter filament for-
mation and force generation, and consequently lead to
activation of the same proliferative pathways identified in the
Acta22/2 SMCs (2). If the ACTA2 missense mutations disrupt
a-SMAfilament polymerization or stability, theremay addition-
ally be increased pools of monomeric actin available to bind
MRTF-A in the cytoplasm, allowing SRF to bind to growth re-
sponsive genes and further drive proliferation.
The proliferative pathways identified in Acta22/2 SMCs
are remarkably similar to well-studied proliferative pathways
in malignant cancer cells. Our findings raise the possibility
that targeted chemotherapeutic drugs blocking proliferative
pathways in cancer cells may be beneficial to patients with oc-
clusive vascular disease caused by hyperplastic SMCs.
Increased proliferation of Acta22/2 SMCs was attenuated
in vitro by both FAK inhibitors and a protein tyrosine
kinase inhibitor, suggesting that proliferation was driven by
both pathways. Since PDGF-BB is a major mitogen for
SMCs and is increased in vivo with vascular injury, we
selected imatinib for a treatment trial to block SMC prolifer-
ation in neointimal lesions in the Acta22/2 mice. Imatinib
prevented neointimal formation in these mice at a dose
lower than that used to reduce tumor growth in mice
(50 mg/kg/day compared with 150 mg/kg/day) (57,58). Inter-
estingly, imatinib blocked neointimal formation in both the
mutant and WT mice. Long-term treatment using imatinib
for chronic myelogenous leukemia and gastrointestinal
stromal tumors has shown that this drug can be given for
years with few serious side effects (59). Imatinib can also
block proliferation in classically de-differentiated populations
of SMCs explanted from porcine coronary arteries (60).
Imatinib trials are currently in progress for pulmonary hyper-
tension, another arterial occlusive disease due to hyper-
proliferative SMCs, and these trials have shown initial
improvement in hemodynamics and functional lung capacity
(61,62). Future studies will determine whether imatinib
therapy may also be beneficial in preventing or limiting the
occlusive vascular lesions in patients with ACTA2 mutations.
MATERIALS ANDMETHODS
Mice
All mouse experiments were carried out in accordance with in-
stitutional guidelines at The University of Texas at Houston
for the care and use of animals. Standard methods were used to
rederive Acta22/2 mice from frozen embryos obtained from
Dr Warren Zimmer at Texas A&M University. Mice were ori-
ginally generated by Schildmeyer et al. (10) and were subse-
quently bred onto a C57 background for ≥ 10 generations.
Figure 7. Proposedmechanisms by which loss of a-actin increases proliferation
and Pdgfr-b expression without inducing SMC dedifferentiation.
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SMC isolation and culture
SMCswere explanted from the ascending and descending aortas
of age- and gender-matched Acta22/2 and WT littermates as
previously described (38). Cells were subcultured in Smooth
Muscle Basal Media containing 20% FBS, pyruvate, HEPES,
L-glutamine, antibiotic and growth factors (SmBM Bullet Kit;
Lonza). Following initial experiments, ascending SMCs were
utilized for the remainder of the studies, and all SMCs were
plated on dishes coated with Type IV collagen (Sigma). Cells
were serum starved for 24 h in culture media with 1% FBS and
all other supplements except growth factors prior to analysis.
Cells from at least three separate explants were analyzed with
similar results, and cells for all experiments were serum-starved
in SmBM containing 1% FBS for 24 h prior to treatment unless
otherwise noted.Cell culture assayswereperformed in triplicate,
and data shown are representative of at least three independent
experiments.
Immunofluorescence
SMCs were seeded at a density of 5000 cells per 22 mm round
cover slip and allowed to attach overnight. Following serum star-
vation, cover slips were fixedwith either 4% paraformaldehyde in
0.1Mphosphate buffer ormethanol–acetone (50/50%).Cellswere
permeabilized in 0.1% Triton X-100 for 10 min and blocked
for 1 h in 5% normal donkey serum, incubated with primary anti-
bodies overnight at 48C and secondary antibodies for 1 h at room
temperature. Primary antibodies were obtained from Millipore
(p397FAK, 1:50), BD Biosciences (p397FAK, 1:200), Sigma
(a-SMA, 1:100; vinculin, 1:200; vinculin-FITC, 1:500) and
Santa Cruz (MRTF-A, 1:50; p53, 1:50). Secondary antibodies
and fluorophores were purchased from Jackson Immunoresearch,
Vector Labs and Invitrogen. High-resolution confocal images
were obtained using aNikonA1Rconfocalmicroscope, and quan-
tifications were performed using NIS Elements software (Nikon).
TIRF microscopy
For quantification of FAproteins, TIRFmicroscopywas utilized
to excite fluorescent proteinswithin90nmof theplasmamem-
brane. The inverted Olympus IX-81 microscope with a TIRF at-
tachment is described in Trache & Lim (2009) (63). A PLAN
APO 60X oil 1.45 NA objective lens was used to acquire
images.We used SlideBook software (Intelligent Imaging Inno-
vations) to measure the FA area and total cell area for each
image. The ratio of FA area to total cell area was calculated for
each cell as previously described in Lim et al. (64), and quanti-
tative data from 10 cells from each condition were pooled.
Immunoblotting and quantitative PCR
Cells plated at equal density were lysed in RIPA buffer contain-
ing phosphatase and protease inhibitors. Total protein quantifi-
cation and immunoblotting were performed using standard
protocols. Antibodies used for immunoblotting were obtained
from Cell Signal (p-ERK1/2, ERK1/2, Pdgfr-b, p-p70S6K,
p70S6K, p-Akt, Akt; all at 1:1000 dilution), Millipore
(p397FAK, 1:750), Santa Cruz (FAK, 1:500; pY1021 Pdgfr-b,
1:500;), Abcam (a-tubulin, 1:1000), Fitzgerald (Gapdh,
1:20,000), Sigma (a-SMA, 1:5000; b-actin, 1:1000; SM 22a,
1:1000) and Novus Biologicals (Calponin-1, 1:1000). Immuno-
blotswere analyzed using ImageJ software (NIH). RNAwas iso-
lated using Tri Reagent (Sigma). CDNA synthesis was
performed using Multiscribe reverse transcriptase and random
primers, and quantitative PCR was performed using Taqman
assays according to the manufacturer’s instructions. All quanti-
tative PCR reagents were purchased from Applied Biosystems.
For protein stability assays, SMCs were treated with cyclohexi-
mide (50 mg/ml), harvested at the indicated time points and ana-
lyzed by immunoblotting.
Carotid artery ligation and in vivo inhibitor treatment
Carotid artery ligations were performed on 8-week-oldWT and
Acta22/2 mice. Mice were anesthetized using intraperitoneal
injection of 2.5% avertin. The left common carotid artery was
ligated near its bifurcation with the use of 5-0 silk sutures.
Animal survival was . 95%. The mice were allowed to
survive 21 days post ligation. Two hours before sacrifice, mice
were injected intraperitoneally with BrdU (Sigma B-5002).
For morphological analysis, animals were perfused with
normal saline and fixed with 10% buffered formalin at physio-
logic pressure for 3 min. Left and right carotid arteries were
removed, further fixed in 10% buffered formalin for 16 h
and paraffin-embedded without further dissection. The entire
length of the left and right carotid arteries was sectioned and
examined for identification of the site with most significant
stenosis. Carotid artery tissues were stained using standard
protocols. Specimens were imaged and photographed using an
Olympus microscope. For morphometric analyses, images of
H&E stained cross-sections of injured and control arteries
were analyzed using Image J (NIH). Perimeters of the lumen, in-
ternal elastic lamina (IEL) and external elastic lamina (EEL)
were obtained by tracing the contours on digitized images
using ImageJ software. Intimal thickness (distance between
lumen and IEL) and medial thickness (distance between IEL
and EEL) were calculated. Percent lumen stenosis was calcu-
lated as: (intima area/IEL area) × 100. For imatinib mesylate
treatment, 50 mg/kg imatinib in dimethyl sulfoxide (DMSO)
or DMSO alone (vehicle) was administered once intraperitone-
ally at 4 h following injury, and once daily for 14 days post
injury. Carotid arteries were harvested for histology 21 days
post injury.
Cell proliferation and migration assays
SMCs were seeded at a density of 5000 cells/well in 96-well
microplates and allowed to attach overnight. Cells were pre-
treated for 30 min in SmBM containing 1% FBS with either
vehicle (DMSO) or the indicated inhibitors before addition of
BrdU, and incubated with BrdU for 24 h. BrdU ELISAS were
performed according to the manufacturer’s instructions (Milli-
pore). Assays were performed in triplicate, and graphs are repre-
sentative of at least three independent experiments.
A modified Boyden chamber assay was used to quantify cell
migration. A total of 50 000 SMCs were seeded in duplicate
into polycarbonate filters (BD Biosciences) fitted into 24-well
plates, with a pore size of 8 × 10-3 mm. The bottom chamber
contained 5 ng/ml PDGF-B as a chemoattractant. Cells were
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incubated for 6 h before gently scraping any unmigrated cells
from the upper surface of the porous membrane and visualizing
migrated cells with 0.5% Crystal Violet. Stained membranes
were mounted onto slides and a blinded observer photographed
five random400xfields fromeachmembrane.Thenumberofmi-
gratory cellswas counted, and resultswere expressed asmean+
SD, representative of at least three independent experiments.
aSKA-fp and aSMA-fp peptide experiments
WTSMCswere seeded onto cover slips as previously described.
After incubation of cells in SmBM containing 1% FBS for 24 h,
cells were treatedwith 10 ng/ml TGF-b1. Forty-eight hours post
TGF-b1 treatment, cells were incubated with 1 mg/ml of either
aSKA-fp or aSMA-fp for 24 h in Owens media. Both peptides
have been previously characterized by Hinz et al. (37). Controls
were treated with Owens media alone. Drug treatments were
added at the same time as peptide. Immunofluorescencewas per-
formedas described aboveusing antibodies againsta-SMA,vin-
culin, MRTF-A and p53; cells were imaged using a Nikon A1
confocalmicroscope, and imageswere quantified usingNISEle-
ments software. For analysis of Pdgfrb expression, quantitative
PCR was carried out as described above.
Flow cytometry
Intracellular ROS levels were quantified using flow cytometry.
Cells were seeded onto collagen IV coated plates, incubated
overnight and serum starved in SmBM with 1% FBS. Cells
were then trypsinized and labeled with Mitosox red (5 mM) for
20 min Probeswerewashed out using PBS, and cells were resus-
pended in PBS for reading on a flow cytometer. Data were ana-
lyzed using CellQuest Pro and Kaluza software.
G-LISA
Cells were seeded and serum starved as previously described.
Cellswere harvested in the provided lysis buffer and snap-frozen
in liquid nitrogen, andG-LISAs forRhoA andRac1were carried
out according to the manufacturer’s instructions (Cytoskeleton,
cat. no. BK-124 and BK-128).
F-to-G actin assays
Cells were seeded and serum starved as previously described.
The ratio of F-to-G actin was determined using an ultracentrifu-
gation method and kit from Cytoskeleton. Cells were harvested
in F-actin lysis buffer and ultracentrifuged according to theman-
ufacturer’s instructions. Equal volumes of supernatant (contain-
ing G-actin) and pellet (containing F-actin) fractions were
electrophoresed, and semi-quantitative analysis was performed
via immunoblotting.
Atomic force microscopy
To determine the stiffness of the cell at the point of contact, the
atomic forcemicroscope (AFM)was operated in forcemode.An
uncoated AFM probe (MLCT, Bruker Nano-Surfaces) was
driven to touch and retract from the cell surface over a known
predefined distance in the z-axis.
The z-axismovement and the deflection signal from the probe
were recorded in a force curve (65). The force curve was ana-
lyzed using Sneddon’s modified Hertz model to obtain the
Young modulus of elasticity at the point of contact (66,67). All
force curves were acquired at a position midway between the
nucleus and the edge of the cell. Measurements were performed
for 2 min per cell, and repeated for more than 10 cells in two dif-
ferent experiments. Thus, over 2000 force curves were acquired
in Nanoscope software (Bruker Nano-Surfaces Inc.) for each
sample. The force curves were processed off-line using
NForceR software [Trzeciakowski JP, Meininger GA.
NForceR: nanoscale force reader and AFM data analysis
package (copyrighted), 2004] followed by PeakFit software
(SYSTAT Software Inc.) analysis.
Statistical analysis
Datawere analyzed using Student’s t-tests or two-wayANOVA,
with P-values ≤ 0.05 considered statistically significant.
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